{"AmendmentNumber":"408","ParentBillNumber":"S3178","Bill":null,"Sponsor":{"Id":"JAC0","Name":"Julian Cyr","Type":1,"Details":"https://malegislature.gov/api/GeneralCourts/194/LegislativeMembers/JAC0","ResponseDate":"2026-07-20T13:42:19.677"},"Category":null,"Action":"Rejected","RollCall":[],"Title":"Kratom Study","Branch":"Senate","RedraftNumber":null,"IsFurther":false,"GeneralCourtNumber":194,"Text":"Mr. Cyr, Ms. Edwards and Mr. O'Connor move that the proposed new text be amended by adding the following section:- \r\nSECTION X. (a) For the purposes of this section, \"kratom\" shall mean a product intended for human consumption containing any part of the leaf of the Mitragyna speciosa plant, or a kratom extract, manufactured as a food, powder, capsule, pill, beverage or other edible product including any material, compound, mixture or preparation containing kratom.\r\n(b) The department of public health shall conduct a study  of kratom use and consider the regulation of kratom in Massachusetts.\r\n(c) The study shall investigate and evaluate:\r\n(1) the public health impacts of kratom consumption, including potential risks of dependency, toxicity, and interactions with other substances;\r\n(2) the current market availability, methods of commercial sale, and target demographics of kratom consumers within the commonwealth; and,\r\n(4) regulatory models implemented by other states; and,\r\n(5) existing and emerging federal policies, guidelines, and legal frameworks governing kratom and its constituent alkaloids, including but not limited to, public health advisories or import alerts issued by the United States Food and Drug Administration, and temporary or permanent scheduling actions taken by the United States Drug Enforcement Administration regarding 7-hydroxymitragynine or synthetic derivatives under the federal Controlled Substances Act.\r\n(d) The department shall submit a report of its findings and recommendations, including recommendations as to the advisability and efficacy of establishing a consumer protection regulatory structure, to the clerks of the house of representatives and the senate and the joint committee on public health, no later than December 31, 2027.\r\n"}